Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Diabetic kidney disease (DKD) is a risk factor for major adverse cardiovascular events (MACE). DKD can be categorized into four phenotypes based on estimated glomerular filtration rate (eGFR, either normal or low) and proteinuria (PR, either negative or positive). This classification is practical as the risks associated with kidney and cardiovascular outcomes, and mortality may vary among the different phenotypes of DKD. This study examined risk of MACE according to the CKD phenotypes in early DKD patients.
The study analyzed 8,018 individuals with type 2 diabetes mellitus (T2DM) from the University of Virginia Health database between 2011 and 2020, excluding those with a high-risk phenotype (eGFR <30 mL/min/1.73 m²) to avoid confusion between cardiovascular events and kidney-related complications. Normal eGFR is characterized as eGFR ≥60 mL/min/1.73 m2, whereas low eGFR is defined as eGFR <60 mL/min/1.73 m2. PR+ is identified as ≥200 mg/g, in contrast to PR– which is defined as <200 mg/g. Participants were categorized into 4 distinct phenotypic categories based on baseline eGFR and PR results and followed for a mean period of 4.5 years (up to 10 years).
During the follow-up period, 1,585 (19.8%) individuals developed MACE. The cumulative incidence of MACE from the index date was highest in the eGFRlowPR– phenotype (23%), followed by eGFRlowPR+ (22%), eGFRnorPR– (15%) and eGFRnorPR+ (12%). CKD phenotype have different impacts on MACE risk. When using the eGFRnorPR– category as a reference, the Odds ratio were 1.71 (95% confidence interval [CI], 1.47 to 1.99) for eGFRlowPR– and 1.61 (95% CI, 1.36 to 1.90) for eGFRlowPR+. However, patients in the category of eGFRnorPR+ exhibited reduced risk [Odds ratio, 0.75 (95% CI, 0.59 to 0.97). Figure 1 showed cumulative hazard of MACE according to CKD phenotypes. Individuals who received SGLT2-inhibitors had a significant reduction in the risk of MACE compared to those who did not received SGLT2-inhibitors [Odds ratio, 0.66 (95% CI, 0.51 to 0.77).
The CKD phenotype, particularly when accompanied by low eGFR, is a stronger indicator of a heightened risk of MACE, whereas a preserved eGFR is associated with fewer MACE events in individuals with T2DM.
